NP137-Lead asset
NP137 is a first-in-class-humanized IGg1 monoclonal antibody directed against netrin-1
NP137 was engineered to specifically and efficiently bind to netrin-1 and to inhibit the interaction between ligand and receptor.
NP137 leads to tumoral cell death and reduces phenotypic plasticity
Netrin-1 functions both as a survival factor and an inducer of Epithelial-to-Mesenchymal Transition (EMT) and its disruption leads to inhibition of tumor growth and EMT. As, EMT is the prerequisite for the formation of metastases and naturally limits the effectiveness of chemotherapies and immune-checkpoint inhibitors. NETRIS Pharma met a significant milestone to demonstrate that NP137 confirmed in preclinical models and on patients its ability to reduce metastases and enhance the anti-tumor activity of these conventional treatments.
NP137 is very well tolerated and is currently investigated in multiple clinical trials
NP137 confirmed an excellent safety profile during the clinical Phase I in monotherapy, while presenting early signs of clinical activity with objective responses and sustained disease stabilization. These signs of clinical activity, together with the confirmation of the reversion of tumoral EMT in patients treated with NP137, have led to conduct an ambitious clinical development plan in combination with chemotherapy and / or immunotherapy in selected indications of high unmet medical need and interest.
